Therapy response prediction of focal cortex stimulation based on clinical parameters: a multicentre,...

Area of Science:

• Neurology
• Biomedical Engineering

Background:

• Focal cortex stimulation (FCS) is a novel European-approved device for focal drug-resistant epilepsy (DRE).
• A previous study showed 17/32 patients achieved ≥50% seizure reduction after 6 months of FCS.
• Currently, no established methods exist to predict FCS treatment response before implantation.

Purpose of the Study:

• To identify predictive biomarkers for FCS treatment response in DRE patients.
• To improve patient selection and counseling for FCS therapy.
• To analyze clinical, imaging, and electrophysiological data for outcome prediction.

Main Methods:

• An ongoing combined retrospective-prospective, non-interventional, multicentre study across 20 epilepsy centers in four European countries.
• Collection of clinical data (seizure frequency/severity, cognition, mood, quality of life, demographics, medical history, medication, FCS parameters) from up to 100 DRE patients.
• Integration of MRI and electroencephalography (EEG) data with multivariate statistical and machine learning analyses to identify predictive biomarkers.

Main Results:

• Analysis is ongoing; specific results on predictive biomarkers are not yet available.
• The study aims to differentiate responders from non-responders based on identified biomarkers.
• Key outcome parameters include seizure reduction, cognitive function, mood, and quality of life.

Conclusions:

• This study seeks to establish reliable methods for predicting FCS treatment response in DRE.
• Identifying predictive biomarkers will enhance patient counseling and optimize the use of FCS therapy.
• The findings are expected to improve outcomes for DRE patients considering FCS.